Klin Padiatr 2022; 234(03): 185-186
DOI: 10.1055/s-0042-1748729
Abstracts

De novo design of growth factor inhibiting proteins

K Maksymenko
1   Max Planck Institute for Biology, Tübingen, Germany
,
J Skokowa
2   University Hospital Tübingen, Tübingen, Germany
,
AN Lupas
1   Max Planck Institute for Biology, Tübingen, Germany
,
N Aghaallaei
2   University Hospital Tübingen, Tübingen, Germany
,
P Müller
3   University of Konstanz, Germany
,
M ElGamacy
1   Max Planck Institute for Biology, Tübingen, Germany
› Author Affiliations
 

Growth factors are signaling molecules coordinating the complex functionality of multicellular organisms during development and homeostasis. Since aberrant expression of growth factors can cause diverse disorders, growth factors and their receptors are central targets for therapeutic modulation. Here, we present two different strategies of computational protein design to obtain inhibitors against growth factors which contribute to tumor progression. Adopting a re-engineering approach, we designed inhibitors of epidermal growth factor (EGF) using a single domain of EGF receptor as a template. Experimental evaluation of two designed candidates revealed that both of them bind EGF with nanomolar affinities and inhibit EGF-induced proliferation of epidermoid carcinoma cell line. Using a de novo design strategy, we designed inhibitors of vascular endothelial growth factor (VEGF). The best designs showed the ability to inhibit proliferation of VEGF-dependent cells in vitro and in zebrafish assays. Thus, our results demonstrate the feasibility of computational protein design approaches to create therapeutic leads in a time- and cost-effective manner.



Publication History

Article published online:
17 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany